Cromos Pharma, where the patients are

Drug Sponsors

Eisai restructures, cuts 180 jobs

Monday, December 2, 2013 01:05 PM

Eisai’s R&D organization, Eisai Product Creation Systems (EPCS), is restructuring and will cut 180 jobs.

More... »

CRF Health eCOA webinar series

HeartWare International acquires CircuLite

Monday, December 2, 2013 12:59 PM

HeartWare International, an innovator of less invasive, miniaturized circulatory support technologies for the treatment of advanced heart failure, has acquired CircuLite, developer of the SYNERGY Circulatory Support System, designed to treat less sick, ambulatory, chronic heart failure patients who are not yet inotrope-dependent.

More... »

SillaJen to acquire Jennerex

Wednesday, November 27, 2013 02:00 PM

SillaJen, a privately-held biotherapeutics and contract research company focused on the development of targeted biological products for cancer, will acquire San Francisco-based Jennerex, a privately-held, clinical-stage biotechnology company developing best-in-class targeted oncolytic immunotherapies for solid tumors.

More... »

Nicox acquires Eupharmed

Wednesday, November 27, 2013 11:48 AM

Nicox, an international pharmaceutical company focused on the ophthalmic market, has acquired Eupharmed, a privately-held Italian ophthalmic company, for $4.8 million in newly issued Nicox shares, plus milestones of up to $3.3 million. The acquisition provides Nicox with an established sales and marketing platform in Italy and a broad portfolio of eye care products. Eupharmed had sales of $4.9 million in 2012 and is expected to see full-year sales of approximately $5.3 million in 2013.

More... »

Flagship VentureLabs launches Seres Health

Friday, November 22, 2013 12:48 PM

Flagship VentureLabs has launched Seres Health after two years of development in stealth mode and $10.5 million in Series A financing during that period from Flagship Ventures and other investors. Seres Health is a clinical-stage therapeutics company developing novel products to treat a host of disease conditions based on novel scientific findings related to the human microbiome. Seres has developed a unique understanding of the functional nature of the human microbiome and has used this knowledge to pioneer Ecobiotic therapeutics, the first class of agents that addresses the ecological nature of the microbiome. 

More... »

Amicus Therapeutics acquires Callidus Biopharma, reduces workforce 14%

Friday, November 22, 2013 12:47 PM

Amicus Therapeutics, a biopharmaceutical company focused on therapies for rare and orphan diseases, has acquired Callidus Biopharma and announced restructuring of its biologics business strategy.

More... »

Cardiome acquires Correvio

Wednesday, November 20, 2013 12:52 PM

Cardiome Pharma has completed the acquisition of Correvio, a privately-held pharmaceutical company in Geneva, to accelerate Cardiome's launch of BRINAVESS (vernakalant IV) and reduce BRINAVESS build out costs.

More... »

Transcept Pharmaceuticals restructures board, cuts six jobs

Friday, November 15, 2013 01:27 PM

Transcept Pharmaceuticals, a specialty pharmaceutical company focused on development and commercialization of proprietary products that address important therapeutic needs in neuroscience, has announced plans to reduce expenses through a reduction in force and a restructuring of its board of directors. Transcept plans to adopt these changes to conserve cash while it evaluates strategies to maximize value for shareholders.

More... »

Dendreon restructures, cuts jobs to 820

Wednesday, November 13, 2013 12:22 PM

Biotech Dendreon has announced a company restructuring that includes cutting employment from 2,000 at its peak to approximately 820.

More... »

Liquidia Technologies launches Envisia Therapeutics

Wednesday, November 13, 2013 12:20 PM

Envisia Therapeutics, a new biotechnology company formed by privately-held Liquidia Technologies, has launched,  backed by $25 million in Series A financing. Envisia will focus on addressing unmet medical needs in various areas of ophthalmology. Envisia’s lead product, ENV515, is an extended-release formulation of a prostaglandin analogue providing glaucoma patients a sustained reduction in intraocular pressure (IOP) over many months after single administration.

More... »

CenterWatch Data Library



Browse by:


April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs